GlassScriptPhysician profile
Troy Andrew Murphy
NPI 1639178395
$5,483.10
in general payments reported to CMS, 2019-2025
41 companies · $958 in 2025
The $958 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $629 · 2021: $690 · 2022: $515 · 2023: $782 · 2024: $1,109 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,078.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $694.43 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $425.57 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $420.28 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $396.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.36 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $244.10 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $218.35 | 2019-2025 | |
| Amgen INC. | $208.68 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $142.58 | 2020-2025 | |
| Idorsia Pharmaceuticals US INC | $140.65 | 2022-2024 | Quviviq |
| Dexcom, INC. | $131.01 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $113.34 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $94.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $72.24 | 2021-2025 | Spravato |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.